Revenue
2022
2023
2024
2025
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Price$0.5300Cached quote
Net income
2019
2019
2020
2020
2021
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2019
2020
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 · Dec 31 | 2021 · Dec 13 | 2020 · Dec 31 | 2020 · Feb 29 | 2019 · Dec 31 | 2019 · Feb 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — |
| Research & development | $11.7M | $22.9M | $31.4M | $22.9M | $4.9M | $4.9M | $295,150 | — | $195,744 | — |
| Operating expenses | $20.2M | $30.8M | $39.5M | $28.2M | $10.1M | $10.1M | $2.4M | $724,740 | $376,860 | $152,789 |
| Operating income | −$20.2M | −$30.8M | −$39.5M | −$28.2M | −$10.1M | −$10.1M | −$2.4M | −$724,740 | −$376,860 | −$152,789 |
| EBITDA | −$19.8M | −$29.9M | −$39.2M | −$28.2M | −$10.1M | — | −$2.4M | — | −$376,215 | — |
| Net income | −$19.9M | −$29.9M | −$39.3M | −$28.3M | −$8.5M | −$8.5M | −$3.8M | $617,903 | −$846,832 | $574,131 |
| Basic EPSper basic share | -$5.48 | -$17.73 | -$1.65 | -$1.45 | -$0.58 | -$0.58 | -$1.24 | -$0.21 | -$0.31 | -$0.04 |
| Diluted EPSper diluted share | -$5.48 | -$18.00 | -$33.00 | -$25.00 | — | -$0.58 | -$1.24 | -$0.21 | -$0.31 | -$0.04 |
Owners
Reported shareholders
0.05%of listed shares
EMC Capital Management6.7K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
EMC Capital Management | 0.05%6.7K shares |
TD Waterhouse Canada Inc. | <0.01%625 shares |
Purpose Unlimited Inc. | <0.01%405 shares |
Mosley Wealth Management | <0.01%1 shares |
Miller Global Investments, LLC | <0.01%1 shares |
Percentages use 13.11M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data